Home > Insider Trading > Filing (0001209191-20-005200)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1668243	Urogen Pharma Ltd.	URGN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1763581	Mark Schoenberg	C/O Urogen Pharma Ltd. 499 Park Avenue New York City NY 10022	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2020-01-26	833	$0.00	9,499	No	4	M	Direct
Ordinary Shares	Disposition	2020-01-27	322	$29.15	9,177	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Restricted Stock Units (RSUs)	Disposition	2020-01-26	833	$0.00	833	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,667			No	4	M	Direct

Footnotes

Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
The transaction reported herein was matchable under Section 16(b) of the Securities and Exchange Act of 1934, to the extent of 322 shares, with the reporting person's purchase of 1,960 ordinary shares of the Issuer at a price of $28.17 per share on November 19, 2019. The reporting person has paid to the Issuer $315.56, representing the full amount of the profit realized in connection with the short-swing transaction.
Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
The reporting person was granted 2,500 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter.